Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer Statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
He, H. et al. Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. Thorac. Cancer 11, 1121–1128 (2020).
Article PubMed PubMed Central Google Scholar
Njei, B., McCarty, T. R. & Birk, J. W. Trends in esophageal cancer survival in United States adults from 1973 to 2009: a SEER database analysis. J. Gastroenterol. Hepatol. 31, 1141–1146 (2016).
Article PubMed PubMed Central Google Scholar
Arnold, M., Soerjomataram, I., Henegouwen, M. B. & Soerjomataram, I. Global incidence of oesophageal cancer and gastric cancer by histology and subsite in 2018. Gut 69, 1564–1571 (2020).
Abnet, C. C., Arnold, M. & Wei, W. Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology 154, 360–373 (2018).
Zang, Z. et al. Dietary patterns and severity of symptom with the risk of esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional latent class analysis. BMC Cancer 22, 95 (2022).
Article CAS PubMed PubMed Central Google Scholar
McCormack, V. A. et al. Informing etiologic research priorities for squamous cell esophageal cancer in Africa: a review of setting-specific exposures to known and putative risk factors. Int. J. Cancer 140, 259–271 (2017).
Article CAS PubMed Google Scholar
Lin, Y. et al. Esophageal cancer in high-risk areas of China: research progress and challenges. Ann. Epidemiol. 27, 215–222 (2017).
Arnal, M. J. D., Arenas, A. F. & Arbeloa, A. L. Esophageal cancer: risk factors, screening and endoscopic treatment in Western and Eastern countries. World J. Gastroenterol. 21, 7933–7943 (2015).
Shah, M. A. et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J. Clin. Oncol. 38, 2677–2694 (2020).
Kojima, T. et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138–4148 (2020).
Article CAS PubMed Google Scholar
Shah, M. A. et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastateic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 5, 546–550 (2019).
Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastroesophageal junction, and oesophageal adenocarcioma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).
Article CAS PubMed PubMed Central Google Scholar
Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942–948 (2022).
Article CAS PubMed PubMed Central Google Scholar
Sun, J. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759–771 (2021).
Article CAS PubMed Google Scholar
Doki, Y., Ajani, J. A., Kato, K. & Xu, J. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449–462 (2022).
Article CAS PubMed Google Scholar
Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191–1203 (2021).
Article CAS PubMed Google Scholar
Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade for HER2-positive gastric cancer. Nature 600, 727–730 (2021).
Article CAS PubMed PubMed Central Google Scholar
Shitara, K. et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N. Engl. J. Med. 382, 2419–2430 (2020).
Article CAS PubMed Google Scholar
Shah, M. A. et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J. Clin. Oncol. 41, 1470–1491 (2023).
Article CAS PubMed Google Scholar
The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
Article PubMed Central Google Scholar
Campbell, J. D. et al. Genomic, pathway network, and immunologic features distinguishing squamous carcinomas. Cell Rep. 23, 194–212 (2018).
Article CAS PubMed PubMed Central Google Scholar
Quante, M., Wang, T. C. & Bass, A. J. Adenocarcinoma of the oesophagus: is it gastric cancer? Gut https://doi.org/10.1136/gutjnl-2022-327096 (2022).
Dotto, G. P. & Rustgi, A. K. Squamous cell cancers: a unified perspective on biology and genetics. Cancer Cell 29, 622–637 (2016).
Article CAS PubMed PubMed Central Google Scholar
Yokoyama, T. et al. Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes, and risk for esophageal squamous cell carcinoma in Japanese men. Cancer Epidemiol. Biomarkers Prev. 12, 1227–1233 (2003).
Wang, G. Q. et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut 54, 187–192 (2005).
Article PubMed PubMed Central Google Scholar
Liu, X. et al. Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma. Gastroenterology 153, 166–177 (2017).
Article CAS PubMed Google Scholar
Liao, G. et al. Single-cell transcriptomics provides insights into the origin and microenvironment of human oesophageal high-grade intraepithelial neoplasia. Clin. Transl. Med. 12, e874 (2022).
Article CAS PubMed PubMed Central Google Scholar
Que, J., Garman, K. S., Souza, R. F. & Spechler, S. J. Pathogenesis and cells of origin of Barrett’s esophagus. Gastroenterology 157, 349–364.e1 (2019).
Nowicki-Osuch, K. et al. Molecular phenotyping reveals the identity of Barrett’s esophagus and its malignant transition. Science 373, 760–767 (2021).
Article CAS PubMed Google Scholar
Sawas, T. et al. Magnitude and time-trend analysis of postendoscopy esophageal adenocarcinoma: a systemic review and meta-analysis. Clin. Gastroenterol. Hepatol. 20, e31–e50 (2022).
Sawas, T. et al. Identification of prognostic phenotypes of esophageal adenocarcinoma in 2 independent cohorts. Gastroenterology 155, 1720–1728 (2018).
Stachler, M. D. et al. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology 155, 156–167 (2018).
Article CAS PubMed Google Scholar
Killcoyne, S. et al. Genomic copy number predicts esophageal cancer years before transformation. Nat. Med. 26, 1726–1732 (2020).
Article CAS PubMed PubMed Central Google Scholar
Fitzgerald, R. C. et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicenter, pragmatic, randomised controlled trial. Lancet 396, 333–344 (2020).
Article PubMed PubMed Central Google Scholar
Wu, W. et al. Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology 144, 956–966 (2013).
Article CAS PubMed Google Scholar
Jammula, S. et al. Identification of subtypes of Barrett’s esophagus and esophageal adenocarcinoma based on DNA methylation profiles and integration of transcriptome and genome data. Gastroenterology 158, 1682–1697 (2020).
留言 (0)